Please be considerate of the feelings of others, and enjoy the supportive and encouraging environment we all share and have a part in maintaining. Guidelines for flair and usernames for those TTC 2 is here. Please also read these mod posts on the subject: Mention of pregnancy or live children is a touchy subject in this forum, but may be discussed in neutral, sensitive language, especially in the context of making an introduction or answering a question about success with a particular treatment protocol.

Statements of medical facts are very helpful ex. Discussion of pregnancies which ended in loss do not need to be confined to the results or beta hell threads. Infertility is stressful, and treatment is jam-packed with crazy-making hormones. Sometimes it's easier to step on peoples' toes than you would expect.

Please consider the probable emotional state of other members before taking offense, or causing it. Infertility is isolating, but here we can come together with other people in the world who really understand what we're going through.

Sometimes members vent jealousy and bitterness that is unacceptable anywhere else. Most of us can understand and empathize, but if you can't, don't bother trying to change it. It is what it is. Infertility is not cute, and it is also necessarily full of medical acronyms. For these reasons, many members find cutesy acronyms to be needlessly confusing and annoying.

Baby dancing is this but we have sex or more often endure painful medical procedures to try to reproduce. Caution should be exercised when using Clomid in patients with uterine fibroids due to the potential for further enlargement of the fibroids. There are no adequate or well-controlled studies that demonstrate the effectiveness of Clomid in the treatment of male infertility.

In addition, testicular tumors and gynecomastia have been reported in males using clomiphene. The cause and effect relationship between reports of testicular tumors and the administration of Clomid is not known. Although the medical literature suggests various methods, there is no universally accepted standard regimen for combined therapy ie, Clomid in conjunction with other ovulation-inducing drugs.

Similarly, there is no standard Clomid regimen for ovulation induction in in vitro fertilization programs to produce ova for fertilization and reintroduction. Therefore, Clomid is not recommended for these uses. Contraindications Hypersensitivity Clomid is contraindicated in patients with a known hypersensitivity or allergy to clomiphene citrate or to any of its ingredients.

Pregnancy Pregnancy Category X Clomid use in pregnant women is contraindicated, as Clomid does not offer benefit in this population. Available human data do not suggest an increased risk for congenital anomalies above the background population risk when used as indicated. However, animal reproductive toxicology studies showed increased embryo-fetal loss and structural malformations in offspring. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential risks to the fetus.

Warnings Visual Symptoms Patients should be advised that blurring or other visual symptoms such as spots or flashes scintillating scotomata may occasionally occur during therapy with Clomid.

These visual symptoms increase in incidence with increasing total dose or therapy duration. These visual disturbances are usually reversible; however, cases of prolonged visual disturbance have been reported with some occurring after Clomid discontinuation.

The visual disturbances may be irreversible, especially with increased dosage or duration of therapy. Patients should be warned that these visual symptoms may render such activities as driving a car or operating machinery more hazardous than usual, particularly under conditions of variable lighting. These visual symptoms appear to be due to intensification and prolongation of afterimages.

Symptoms often first appear or are accentuated with exposure to a brightly lit environment. While measured visual acuity usually has not been affected, a study patient taking mg Clomid daily developed visual blurring on the 7th day of treatment, which progressed to severe diminution of visual acuity by the 10th day.

No other abnormality was found, and the visual acuity returned to normal on the 3rd day after treatment was stopped.

Ophthalmologically definable scotomata and retinal cell function electroretinographic changes have also been reported. A patient treated during clinical studies developed phosphenes and scotomata during prolonged Clomid administration, which disappeared by the 32nd day after stopping therapy. While the etiology of these visual symptoms is not yet understood, patients with any visual symptoms should discontinue treatment and have a complete ophthalmological evaluation carried out promptly.

Ovarian Hyperstimulation Syndrome The ovarian hyperstimulation syndrome OHSS has been reported to occur in patients receiving clomiphene citrate therapy for ovulation induction. OHSS may progress rapidly within 24 hours to several days and become a serious medical disorder. In some cases, OHSS occurred following cyclic use of clomiphene citrate therapy or when clomiphene citrate was used in combination with gonadotropins.

Transient liver function test abnormalities suggestive of hepatic dysfunction, which may be accompanied by morphologic changes on liver biopsy, have been reported in association with OHSS. OHSS is a medical event distinct from uncomplicated ovarian enlargement. The clinical signs of this syndrome in severe cases can include gross ovarian enlargement, gastrointestinal symptoms, ascites, dyspnea, oliguria, and pleural effusion.

In addition, the following symptoms have been reported in association with this syndrome: The early warning signs of OHSS are abdominal pain and distention, nausea, vomiting, diarrhea, and weight gain. Elevated urinary steroid levels, varying degrees of electrolyte imbalance, hypovolemia, hemoconcentration, and hypoproteinemia may occur. Death due to hypovolemic shock, hemoconcentration, or thromboembolism has occurred. Due to fragility of enlarged ovaries in severe cases, abdominal and pelvic examination should be performed very cautiously.

If conception results, rapid progression to the severe form of the syndrome may occur. To minimize the hazard associated with occasional abnormal ovarian enlargement associated with Clomid therapy, the lowest dose consistent with expected clinical results should be used.

Maximal enlargement of the ovary, whether physiologic or abnormal, may not occur until several days after discontinuation of the recommended dose of Clomid. Some patients with polycystic ovary syndrome who are unusually sensitive to gonadotropin may have an exaggerated response to usual doses of Clomid.

If enlargement of the ovary occurs, additional Clomid therapy should not be given until the ovaries have returned to pretreatment size, and the dosage or duration of the next course should be reduced. Ovarian enlargement and cyst formation associated with Clomid therapy usually regresses spontaneously within a few days or weeks after discontinuing treatment. The potential benefit of subsequent Clomid therapy in these cases should exceed the risk.

Unless surgical indication for laparotomy exists, such cystic enlargement should always be managed conservatively.

A causal relationship between ovarian hyperstimulation and ovarian cancer has not been determined. However, because a correlation between ovarian cancer and nulliparity, infertility, and age has been suggested, if ovarian cysts do not regress spontaneously, a thorough evaluation should be performed to rule out the presence of ovarian neoplasia. Precautions General Careful attention should be given to the selection of candidates for Clomid therapy.

Information for Patients The purpose and risks of Clomid therapy should be presented to the patient before starting treatment. It should be emphasized that the goal of Clomid therapy is ovulation for subsequent pregnancy. The physician should counsel the patient with special regard to the following potential risks: Visual Symptoms Advise that blurring or other visual symptoms occasionally may occur during or shortly after Clomid therapy.

It should be made clear to the patient that, in some instances, visual disturbances may be prolonged, and possibly irreversible, especially with increased dosage or duration of therapy. Warn that visual symptoms may render such activities as driving a car or operating machinery more hazardous than usual, particularly under conditions of variable lighting see WARNINGS. The patient should be instructed to inform the physician whenever any unusual visual symptoms occur.

If the patient has any visual symptoms, treatment should be discontinued and complete ophthalmologic evaluation performed. To minimize the risks associated with ovarian enlargement, the patient should be instructed to inform the physician of any abdominal or pelvic pain, weight gain, discomfort, or distention after taking Clomid see WARNINGS.

Tags: buy requip 0.25mg cheapest generic cialis no prescription

© Copyright 2017 Clomid anxiety disorder - Approved Meds Online.